• Follow
  • Follow
  • Follow
  • Follow
U

Search



Shop

w

News

w

Blog

DONATE
Team Jack Foundation
  • About Us
    • Our Mission
    • Jack Hoffman
    • Board & Staff
    • Financials
  • Our Impact
    • Scientific Advisory Board
    • Sponsored Grants
    • Research Articles
  • Brain Cancer
    • What is Brain Cancer?
      • What is DIPG?
    • Brain Cancer Facts
    • Cancer Awareness Months
      • Brain Tumor Awareness Month
    • Family Resources
  • Events
  • Get Involved
    • Fundraise
      • Host an Event
      • Run For Team Jack
      • Birthday Fundraiser
    • Give
    • Our Sponsors
    • Volunteer
  • Heroes
  • Donate
  • Shop
  • Blog
  • News
Select Page

Get Involved

Clinical Trial Finder

Search Results

Post-Authorization Long-Term Safety Study of LUTATHERA

Study Purpose

Study to assess the long-term safety of LUTATHERA for the labeled indication (SmPC/USPI).

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Observational
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - adult patients (fulfilling the definition of "age of majority" per local regulations), - with unresectable or metastatic, well-differentiated, somatostatin receptor positive GEP-NETs.
  • - and who were treated with Lutathera (regardless of the quantity and number of doses administered and whatever the reasons for ending).

Exclusion Criteria:

  • - Hypersensitivity to Lutathera (active substance or any of the excipients), - presence of established or suspected pregnancy or pregnancy not excluded, - presence of kidney failure with creatinine clearance < 30 mL/min.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT03691064
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Advanced Accelerator Applications
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Study Director
Principal Investigator Affiliation Advanced Accelerator Applications
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Active, not recruiting
Countries France, Portugal, Spain, United Kingdom, United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Neuroendocrine Tumors
Additional Details

To assess the incidence and nature of potential long-term safety outcomes in patients with unresectable or metastatic, well-differentiated, somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours. Retrospective and prospective data will be used.

Arms & Interventions

Arms

: LUTATHERA

Treated per labeled LUTATHERA dosing regimen.

Interventions

Drug: - LUTATHERA

Labeled dosing regimen: 7.4 gigaBecquerel (GBq) (200 milliCurie [mCi]) every 8 weeks for a total of 4 doses.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Banner MD Anderson Cancer Center, Phoenix, Arizona

Status

Address

Banner MD Anderson Cancer Center

Phoenix, Arizona, 85006

Portland, Ohio

Status

Address

The Ohio State University Wexner Medical Center

Portland, Ohio, 43210

Portland, Oregon

Status

Address

Oregon Health & Sciences University Hospital

Portland, Oregon, 97339

Virginia Mason in Seattle, Seattle, Washington

Status

Address

Virginia Mason in Seattle

Seattle, Washington, 98101

International Sites

Novartis Investigative site, Clichy, France

Status

Address

Novartis Investigative site

Clichy, ,

Novartis Investigative site, Lyon, France

Status

Address

Novartis Investigative site

Lyon, ,

Novartis Investigative site, Villejuif, France

Status

Address

Novartis Investigative site

Villejuif, ,

Novartis Investigative site, Coimbra, Portugal

Status

Address

Novartis Investigative site

Coimbra, , 3000-075

Novartis Investigative site, Santiago de Compostela, La Corunya, Spain

Status

Address

Novartis Investigative site

Santiago de Compostela, La Corunya, 15706

Novartis Investigative site, Majadahonda, Madrid, Spain

Status

Address

Novartis Investigative site

Majadahonda, Madrid, 28222

Novartis Investigative site, Birmingham, United Kingdom

Status

Address

Novartis Investigative site

Birmingham, , B152WB

Novartis Investigative site, Cambridge, United Kingdom

Status

Address

Novartis Investigative site

Cambridge, , CB2 0QC

Novartis Investigative site, Glasgow, United Kingdom

Status

Address

Novartis Investigative site

Glasgow, , G12 OYN

Novartis Investigative site, Liverpool, United Kingdom

Status

Address

Novartis Investigative site

Liverpool, , L7 8XP

Novartis Investigative site, London, United Kingdom

Status

Address

Novartis Investigative site

London, , NW32QG

Novartis Investigative site, London, United Kingdom

Status

Address

Novartis Investigative site

London, , SE1 9RT

Novartis Investigative site, London, United Kingdom

Status

Address

Novartis Investigative site

London, , SE5 9RS

Novartis Investigative site, London, United Kingdom

Status

Address

Novartis Investigative site

London, , W6 8RF

Novartis Investigative site, Manchester, United Kingdom

Status

Address

Novartis Investigative site

Manchester, ,

Novartis Investigative site, Scheffield, United Kingdom

Status

Address

Novartis Investigative site

Scheffield, , S102SJ

Resources

  • Patient and Caregiver Survey
  • Clinical Trial Endpoints
  • Research Resources
Powered By

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.

Make an impact through your inbox

News, upcoming events and research updates delivered straight to your inbox.

  • This field is for validation purposes and should be left unchanged.
MAKE AN IMPACT

Donate today to help the Team Jack Foundation fund research and fight pediatric brain cancer.

Make a Donation
  • About Us
  • Our Mission
  • Jack Hoffman
  • Board & Staff
  • Fund Allocation
  • Financials
  • Our Impact
  • Scientific Advisory Board
  • Sponsored Grants
  • Research Articles
  • Brain Cancer
  • Family Resources
  • Get Involved
  • Fundraise
  • Give
  • Events
  • Our Sponsors
  • Volunteer
  • Follow
  • Follow
  • Follow
  • Follow
  • Follow
seal of transparency badge - 2019 Gold
combined health agencies drive member charity badge
Share Omaha member badge
© 2021 Team Jack Foundation. PO Box 607, Atkinson, NE, 68713. All Rights Reserved. Team Jack Foundation, Inc. is exempt from federal income tax under section 501(c)3, ID Number 46-2301134, of the internal revenue code. All contributions to the Foundation are tax deductible. Privacy Policy • Contact